Introduction {#s1}
============

Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a newly recognized acute autoimmune encephalitis caused by anti-neuronal autoantibodies, which affects mainly children and young adult females ([@B1], [@B2]). Its typical clinical manifestations include a progressive development of neurologic and psychiatric symptoms, including abnormal movements, seizures, impaired memory, and behavior disorders ([@B2], [@B3]). Anti-NMDAR encephalitis is usually associated with teratoma and often secondary to CNS infection caused by viruses or parasites ([@B4], [@B5]). Some studies have suggested that anti-NMDAR antibodies initiate the innate immune response and promote sterile neuroinflammation which leads to the lesioning of brain tissues ([@B6], [@B7]). However, one of the major challenges in the management of anti-NMDAR encephalitis is to identify biomarkers with diagnostic and prognosis predicting value.

Mitochondrial DNA (mtDNA) is a damage-associated molecular pattern molecule (DAMP) that can trigger activation of the human innate immune system and initiate an inflammatory response ([@B8], [@B9]). Usually, the basal level of CSF cell-free mtDNA stays low and reflects the normal turnover of mtDNA in the brain, whereas elevated CSF levels of mtDNA were reported in patients with traumatic brain injury and multiple sclerosis. This indicates that mtDNA plays a mediatory role in sterile inflammatory responses ([@B10], [@B11]). Thus, it is crucial to evaluate the profile of cell-free mtDNA in anti-NMDAR encephalitis and its potential relationship with the pathophysiology of this disease. In this study, we investigated the cell-free mtDNA profile in the CSF of patients with anti-NMDAR encephalitis vs. other non-inflammatory neurological disorders including peripheral nerve disease and hysteria. We further examined possible associations of their cell-free mtDNA profiles with the modified Rankin Scale (mRS) score and their cytokine profiles, including IL-6, IL-10, and TNF-α ([@B12]).

Materials and Methods {#s2}
=====================

Patients and Controls
---------------------

We recruited a total of 33 patients from the Department of Neurology, Nanfang Hospital, Southern Medical University, according to inclusion criteria based on the revised anti-NMDAR encephalitis diagnosis criteria of Graus et al. published in 2016 ([@B2], [@B13]). Specifically, all anti-NMDAR encephalitis patients were treatment-naïve, and their CSF was sampled at acute onset with confirmation of positive antibodies against the NR1 subunit of the NMDAR by cell-based analysis and negative for viral DNA and other pathogens. All the patients\' CSF were negative for the detection of tuberculosis, cryptococcus, and some common viruses by PCR. All patients with anti-NMDAR encephalitis were treated with first-line treatment or combined second-line treatment ([@B1]). The control group consisted of a cohort of 17 age- and gender-matched patients with confirmed other non-inflammatory neurological disorders. Patients were tested negative for CSF antibodies against the NR1 subunit of the NMDAR. This study was conducted with the approval (NFEC-2018-095) of the Ethics Committee of Nanfang Hospital, Southern Medical University. Written informed consent was obtained from all patients for this study.

CSF Collection and DNA Preparation
----------------------------------

All 33 patients and the 17 control individuals were subjected to lumbar puncture for CSF analysis within 3 days of their admission; 15 of the 33 patients with anti-NMDAR encephalitis received another lumbar puncture for CSF re-evaluation at 6 months follow-up after discharge. CSF samples were processed within 30 min of collection and centrifuged at 1,000 g for 10 min. The CSF supernatants were then transferred to polypropylene tubes and stored at −80°C. DNA was extracted from supernatants using the QIAmp DNA Mini Kit (Qiagen GmbH).

Quantitation of CSF Cell-Free mtDNA
-----------------------------------

The assessment of concentration of mtDNA was performed by quantitative polymerase chain reaction (qPCR) ([Supplementary Material](#SM1){ref-type="supplementary-material"}) ([@B11]). Each measurement consisted of biological duplicates and technical triplicates; the samples from anti-NMDAR encephalitis patients and control individuals were randomized to avoid batch effects.

Determination of Inflammatory Cytokine Levels
---------------------------------------------

The levels of inflammation-associated cytokines were quantified using Sandwich ELISA kits \[Bender MedSystems GmbH (IL-6 and IL-10) (Vienna, Austria) and Cusabio (TNF-α) (Wuhan, China)\] according to the manufacturers\' instructions ([Supplementary Material](#SM1){ref-type="supplementary-material"}).

Evaluation of mRS
-----------------

The mRS score was evaluated for neurologic disabilities ([@B14]). All 33 patients with anti-NMDAR encephalitis were evaluated for mRS scores at the times of their admission, while 15 patients received re-evaluation for mRS scores at their 6-month follow-up.

Statistical Analysis
--------------------

Data were expressed as mean ± SD or the median (range). Statistical analyses were performed using SPSS version 20.0 (IBM Corp, Armonk, NY, USA). Independent-samples non-parametric tests were performed to compare the levels of CSF cell-free mtDNA or inflammatory cytokines between patients and controls. Paired *t*-tests were performed to compare parameters in the 15 patients at their admission vs. follow-up. Correlations among the quantitative parameters were evaluated using Pearson\'s test; correlations between mRS scores and quantitative parameters were assessed with Spearman\'s test. A *p* \< 0.05 was regarded as statistically significant.

Results {#s3}
=======

Demographic and Clinical Features of Anti-NMDAR Encephalitis Patients
---------------------------------------------------------------------

The demographic data and clinical features of patients (*n* = 33) and controls (*n* = 17) are shown in [Table 1](#T1){ref-type="table"}. All patients were confirmed by positive detection of anti-NMDAR autoantibodies in their CSF. Psychiatric symptoms (85%), electroencephalogram (EEG) abnormality (76%), and seizure onset (64%) were the most common clinical presentations in the patients with anti-NMDAR encephalitis. The other symptoms include fever, autonomic disturbances, disturbance of consciousness, abnormal movements, and so on. These patients with fever were neither identified with clues of bacterial infection nor increased levels of C reactive protein or procalcitonin. Notably, compared with their peak mRS scores at admission, the mRS scores at 6-month follow up in the 15 follow-up patients were significantly lower (paired *t*-test, *p* \< 0.001), indicating the effectiveness of treatment.

###### 

Clinic manifestations and characteristics of anti-NMDAR encephalitis and controls.

                                                 **NMDAR (*n* = 33)**   **Control (*n* = 17)**
  ---------------------------------------------- ---------------------- --------------------------------------------------------
  Gender (male/female)                           14/19                  8/9
  Age (years, mean)                              34.8 ± 17.6            35.0 ± 15.3
  **PSYCHIATRIC AND NEUROLOGIC SYMPTOMS**                               
  Fever                                          19 (58%)               --
  Disorders of memory, behavior, and cognition   28 (85%)               --
  Seizures                                       21 (64%)               --
  Autonomic disturbances                         13 (39%)               --
  Disturbance of consciousness                   20 (61%)               --
  Abnormal movements                             16 (48%)               --
  Abnormal electroencephalogram                  25 (76%)               --
  Ovarian teratoma                               2 (6%)                 --
  **CSF ASSESSMENT**                                                    
  White blood cell count( × 10^6^/L, median)     3 (0, 17.5)            0 (0, 0)[^\*\*^](#TN1){ref-type="table-fn"}
  Protein (g/L, median)                          0.28 (0.16, 0.58)      0.32 (0.21, 0.38)
  IL-6(pg/ml, median)                            7.30 (3.85, 13.40)     2.90 (2.60, 3.85)[^\*\*\*^](#TN2){ref-type="table-fn"}
  IL-10(pg/ml, median)                           4.91 (3.64, 5.79)      0.91 (0.00, 1.13)[^\*\*\*^](#TN2){ref-type="table-fn"}
  TNF-α(pg/ml, median)                           6.03 (4.33, 11.34)     1.23 (0.19, 2.30)[^\*\*\*^](#TN2){ref-type="table-fn"}
  **mRS SCORES**                                                        
  Maximum mRS scores                             4 (4, 5)               --
  6-months mRS scores                            3 (2, 3.5)             --
  Anti-NMDAR antibody                            33                     0

p \< 0.01;

*p \< 0.001*.

Cell-Free mtDNA and Inflammatory Cytokines in the CSF of Anti-NMDAR Encephalitis Patients
-----------------------------------------------------------------------------------------

To investigate the role of cell-free mtDNA in anti-NMDAR encephalitis, we evaluated the CSF levels of cell-free mtDNA in these patients (*n* = 33) and controls (*n* = 17) using a qPCR assay. As shown in [Figure 1A](#F1){ref-type="fig"}, the copy number of CSF cell-free mtDNA was significantly elevated in anti-NMDAR encephalitis patients at the acute stage (258.2 copies/10 μl: 148.7, 461.3) compared to controls (73.6 copies/10 μl; 51.8, 95.1) (*p* \< 0.001). To further evaluate the role of humoral immunity in anti-NMDAR encephalitis, we measured the CSF levels of inflammation-related cytokines, IL-6, IL-10, and TNF-α by ELISA. The ELISA data showed that the levels of pro-inflammatory cytokines IL-6 and TNF-α, as well as the anti-inflammatory cytokine IL-10, were significantly higher in patients with anti-NMDAR encephalitis compared with controls (*p* \< 0.001, \<0.001, \<0.001, respectively) ([Table 1](#T1){ref-type="table"}, [Figures 1B--D](#F1){ref-type="fig"}).

![Changes of CSF mtDNA and inflammatory cytokines in anti-NMDAR encephalitis**. (A)** The q-PCR assessment of CSF levels of mtDNA showed elevated cell-free mtDNA copies in patients with anti-NMDAR encephalitis (NMDAR) vs. controls (CTL), while the levels of inflammation-related cytokines, IL-6 **(B)**, IL-10 **(C)**, and TNF-α **(D)** were also significantly changed in anti-NMDAR encephalitis. The *p*-values were indicated within figures. ROC analysis showed that when the cut-off value was set as 91.55 copies/10 μL, the sensitivity of CSF cell-free mtDNA test was 100% and the specificity was 76.5%, and the area under ROC curve (AUC^ROC^) was 0.964 (95% CI: 0.919--1.010, *p* \< 0.0001) **(E)**. Potential correlations were analyzed between the patient\' mRS scores acquired at their peak presentations (peak mRS) and 6-month follow-up (6 m mRS) to their corresponding CSF levels of cell-free mtDNA **(F)**.](fimmu-10-00103-g0001){#F1}

Furthermore, the receiver operating characteristic (ROC) curve analysis of cell-free mtDNA as a diagnostic biomarker of anti-NMDAR encephalitis showed that the sensitivity was 100% and the specificity was 76.5% when 91.55 copies/10 μl was selected as the cut-off value. Area under the ROC curve (AUC^ROC^) was 0.964 (95% CI: 0.919--1.010, *p* \< 0.001) ([Figure 1E](#F1){ref-type="fig"}).

Altered CSF Levels of Cell-Free mtDNA and Inflammatory Cytokines in the Course of the Disease
---------------------------------------------------------------------------------------------

The levels of CSF cell-free mtDNA in patients dropped significantly from 318.6 ± 196.7 copies/10 μl (peak) to 212.2 ± 129.8 copies/10 μl at 6-month follow up (*p* = 0.003), while the latter was still higher compared to controls (*p* \< 0.001). The levels of CSF IL-6, IL-10, and TNF-α were also significantly reduced at 6-month follow up compared to that at the acute stage of anti-NMDAR encephalitis (*p* = 0.005, 0.003, \<0.001, respectively).

The Relationship Between CSF Levels of Cell-Free mtDNA and Inflammatory Cytokines in Anti-NMDAR Encephalitis
------------------------------------------------------------------------------------------------------------

Correlation analysis was performed to demonstrate changes in the DAMP molecule, cell-free mtDNA with humoral immunity sponsors, e.g., IL-6, IL-10, and TNF-α. The analysis showed that there was a statistically significant correlation of CSF cell-free mtDNA with IL-6 (*r* = 0.307, *p* = 0.041), but neither with IL-10 (*r* = −0.085, *p* = 0.319) nor TNF-α (*r* = −0.050, *p* = 0.391) in the acute stage of anti-NMDAR encephalitis.

Relationship Between CSF Levels of Cell-Free mtDNA and Clinical Outcome in Anti-NMDAR Encephalitis
--------------------------------------------------------------------------------------------------

The relationships between clinical outcome, mRS scores, and CSF levels of cell-free mtDNA, IL-6, IL-10, and TNF-α in patients with anti-NMDAR encephalitis were evaluated. There were significant positive correlations between CSF levels of cell-free mtDNA and mRS scores at both the acute stage (*r* = 0.744, *p* = 0.000) and the 6-month follow up (*r* = 0.576, *p* = 0.000, [Figure 1F](#F1){ref-type="fig"}). However, no significant correlation was shown between the CSF levels of cell-free mtDNA and three cytokines IL-6, IL-10, and TNF-α, or clinical outcome.

Discussion {#s4}
==========

In this cross-sectional study, we report for the first time the identification of cell-free mtDNA as a potential biomarker of mitochondrial damage in anti-NMDAR encephalitis. Our data demonstrating significantly increased CSF cell-free mtDNA suggests that cell-free mtDNA may participate in the pathogenesis of this disease, which in turn could reflect the severity of neurological impairment.

Both the innate and acquired immune system play a role in the pathogenesis of anti-NMDAR encephalitis ([@B6]). The innate immune system recognizes endogenous damage-associated molecular pattern (DAMP) molecules and exogenous pathogen-associated molecular pattern (PAMP) molecules, which will initiate a non-infectious or a pathogen-induced inflammatory response, correspondingly ([@B15]). Since mitochondria are evolutionarily derived from bacteria by endosymbiosis and therefore bear bacterial molecular motifs ([@B15]), mtDNA is considered an activator of the innate immune system. The mtDNA is a DAMP molecule that can initiate antimicrobial responses and inflammatory pathology ([@B16]) in various situations, such as shock, injury, infection, and cancer ([@B15], [@B17]--[@B19]). Cell-free mtDNA can be recognized by pattern-recognition receptors (PRRs), usually the toll-like receptor-9 (TLR-9) ([@B8], [@B15]) and result in increased expressions of inflammatory cytokines and pro-inflammatory molecules ([@B9], [@B18], [@B20]).

The anti-inflammatory cytokine IL-6 is increased in neuronal and CNS autoimmune diseases, such as neuromyelitis optica and multiple sclerosis ([@B21], [@B22]). Mechanistically, IL-6 stimulates B-cell differentiation, promotes the survival of plasmablasts, and enhances the intrathecal production of anti-NMDAR antibodies ([@B12], [@B23], [@B24]). Here, we demonstrated that the CSF level of IL-6 was significantly increased and positively correlated with CSF mtDNA levels in anti-NMDAR encephalitis. However, the other two inflammatory cytokines, IL-10 and TNF-α lack correlation with changes of CSF mtDNA though they also increased in the patients with anti-NMDAR encephalitis. These findings suggest that while cytokines may play an essential role in the pathogenesis of anti-NMDAR encephalitis, IL-6 may specifically act as a downstream molecule of the mtDNA mediated immune response.

Since a positive prognosis of anti-NMDAR encephalitis is closely linked to early treatment, early diagnosis of this disease is crucial. CSF biomarkers that have a strong correlation with the prognosis of anti-NMDAR encephalitis would be particularly useful in the assessment of the severity and evaluation of recovery for patients. In this study, we demonstrated that the CSF levels of cell-free mtDNA positively correlated with both the maximum and 6-month follow up mRS scores. This suggests that a higher level of CSF cell-free mtDNA may indicate a more severe clinical presentation and worse prognosis of anti-NMDAR encephalitis. Therefore, changes in CSF cell-free mtDNA, combined with changes in anti-NMDAR antibody titer, may become a promising indicator for prognosis predicting and monitoring in anti-NMDAR encephalitis.

CSF cytotoxicity has been thought to be a cause of certain neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) ([@B25]). Transfering the CSF of ALS pathients to rat cerebral ventricle could provoke changes similar to those found in the disease ([@B26]). Though the pathogenesis of anti-NMDAR encephalitis is not all clear, tumor is though to be associated with anti-NMDAR encephalitis. CNS infections were also thought as immunological triggers in some cases, especially in relapse post-herpes simplex virus encephalitis ([@B4], [@B27]). In the present study, all the patients\' CSF were negative for the detection of tuberculosis, cryptococcus, and some common viruses by PCR. The correlation between mitochondrial DNA and infection needs to be clarified in further studies.

Yet, this result has some limitations: the control group comprised subjects with non-inflammatory CNS diseases. It may be better to include a control cohort with viral encephalitis since it is initiated by PAMP, which usually mimics presentations of anti-NMDAR encephalitis. Future studies should include a control group of subjects with PAMP related encephalitis.

Conclusion {#s5}
==========

This report details, for the first time, the role of CSF cell-free mtDNA in anti-NMDAR encephalitis. Our findings suggest that CSF cell-free mtDNA may be implicated in the pathogenesis of anti-NMDAR encephalitis. In addition, CSF cell-free mtDNA may also act as a prognostic biomarker as it correlated positively with mRS scores and indicated that higher levels of CSF cell-free mtDNA were associated with more severe clinical presentations and a worse prognosis.
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